391 related articles for article (PubMed ID: 31533771)
21. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta.
Orwoll ES; Shapiro J; Veith S; Wang Y; Lapidus J; Vanek C; Reeder JL; Keaveny TM; Lee DC; Mullins MA; Nagamani SC; Lee B
J Clin Invest; 2014 Feb; 124(2):491-8. PubMed ID: 24463451
[TBL] [Abstract][Full Text] [Related]
23. Bisphosphonate therapy for osteogenesis imperfecta.
Phillipi CA; Remmington T; Steiner RD
Cochrane Database Syst Rev; 2008 Oct; (4):CD005088. PubMed ID: 18843680
[TBL] [Abstract][Full Text] [Related]
24. Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study.
Otaify GA; Aglan MS; Ibrahim MM; Elnashar M; El Banna RA; Temtamy SA
Osteoporos Int; 2016 Jan; 27(1):81-92. PubMed ID: 26138583
[TBL] [Abstract][Full Text] [Related]
25. Oral bisphosphonate treatment for osteogenesis imperfecta--an Indian perspective.
Shah I; Johari A
Ann Trop Paediatr; 2007 Mar; 27(1):39-43. PubMed ID: 17469731
[TBL] [Abstract][Full Text] [Related]
26. Acute and long-term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational Spanish study with five years of follow-up.
Pavón de Paz I; Rosado Sierra JA; Pérez Blanco C; Modroño Móstoles N; Guijarro de Armas G; Navea Aguilera C
Endocrinol Diabetes Nutr (Engl Ed); 2019 Feb; 66(2):108-116. PubMed ID: 30077631
[TBL] [Abstract][Full Text] [Related]
27. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
Land C; Rauch F; Travers R; Glorieux FH
Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
[TBL] [Abstract][Full Text] [Related]
28. Oral Bisphosphonate Therapy for Osteogenesis Imperfecta: A Systematic Review and Meta-Analysis of Six Randomized Placebo-Controlled Trials.
Ying ZM; Hu B; Yan SG
Orthop Surg; 2020 Aug; 12(4):1293-1303. PubMed ID: 32589343
[TBL] [Abstract][Full Text] [Related]
29. Scoliosis in osteogenesis imperfecta caused by COL1A1/COL1A2 mutations - genotype-phenotype correlations and effect of bisphosphonate treatment.
Sato A; Ouellet J; Muneta T; Glorieux FH; Rauch F
Bone; 2016 May; 86():53-7. PubMed ID: 26927310
[TBL] [Abstract][Full Text] [Related]
30. Bone densitometry in pediatric patients treated with pamidronate.
Grissom LE; Kecskemethy HH; Bachrach SJ; McKay C; Harcke HT
Pediatr Radiol; 2005 May; 35(5):511-7. PubMed ID: 15655696
[TBL] [Abstract][Full Text] [Related]
31. A comparative study of quality of life, functional and bone outcomes in osteogenesis imperfecta with bisphosphonate therapy initiated in childhood or adulthood.
Feehan AG; Zacharin MR; Lim AS; Simm PJ
Bone; 2018 Aug; 113():137-143. PubMed ID: 29787832
[TBL] [Abstract][Full Text] [Related]
32. Management of atypical femoral fracture in a patient with osteogenesis imperfecta.
Tan JY; Seow CJ
BMJ Case Rep; 2017 Dec; 2017():. PubMed ID: 29269360
[TBL] [Abstract][Full Text] [Related]
33. Treatment with neridronate in children and adolescents with osteogenesis imperfecta: Data from open-label, not controlled, three-year Italian study.
Idolazzi L; Fassio A; Viapiana O; Rossini M; Adami G; Bertoldo F; Antoniazzi F; Gatti D
Bone; 2017 Oct; 103():144-149. PubMed ID: 28684193
[TBL] [Abstract][Full Text] [Related]
34. Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta.
Aström E; Jorulf H; Söderhäll S
Arch Dis Child; 2007 Apr; 92(4):332-8. PubMed ID: 17114205
[TBL] [Abstract][Full Text] [Related]
35. Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study.
Rauch F; Munns CF; Land C; Cheung M; Glorieux FH
J Bone Miner Res; 2009 Jul; 24(7):1282-9. PubMed ID: 19257821
[TBL] [Abstract][Full Text] [Related]
36. BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial.
Glorieux FH; Devogelaer JP; Durigova M; Goemaere S; Hemsley S; Jakob F; Junker U; Ruckle J; Seefried L; Winkle PJ
J Bone Miner Res; 2017 Jul; 32(7):1496-1504. PubMed ID: 28370407
[TBL] [Abstract][Full Text] [Related]
37. First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI.
Semler O; Netzer C; Hoyer-Kuhn H; Becker J; Eysel P; Schoenau E
J Musculoskelet Neuronal Interact; 2012 Sep; 12(3):183-8. PubMed ID: 22947550
[TBL] [Abstract][Full Text] [Related]
38. Cyclic pamidronate therapy in children with osteogenesis imperfecta.
Salehpour S; Tavakkoli S
J Pediatr Endocrinol Metab; 2010; 23(1-2):73-80. PubMed ID: 20432809
[TBL] [Abstract][Full Text] [Related]
39. Approach to the Patient: Pharmacological Therapies for Fracture Risk Reduction in Adults With Osteogenesis Imperfecta.
Liu W; Lee B; Nagamani SCS; Nicol L; Rauch F; Rush ET; Sutton VR; Orwoll E
J Clin Endocrinol Metab; 2023 Jun; 108(7):1787-1796. PubMed ID: 36658750
[TBL] [Abstract][Full Text] [Related]
40. Osteogenesis Imperfecta Type VI in Individuals from Northern Canada.
Ward L; Bardai G; Moffatt P; Al-Jallad H; Trejo P; Glorieux FH; Rauch F
Calcif Tissue Int; 2016 Jun; 98(6):566-72. PubMed ID: 26815784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
